The Influence of the FFAR4 Agonist TUG-891 on Liver Steatosis in ApoE-Knockout Mice

[1]  Dongqin Chen,et al.  sSTEAP4 regulates cellular homeostasis and improves high-fat-diet-caused oxidative stress in hepatocytes. , 2022, Life sciences.

[2]  J. Totoń-Żurańska,et al.  Inhibition of Atherosclerosis and Liver Steatosis by Agmatine in Western Diet-Fed apoE-Knockout Mice Is Associated with Decrease in Hepatic De Novo Lipogenesis and Reduction in Plasma Triglyceride/High-Density Lipoprotein Cholesterol Ratio , 2021, International journal of molecular sciences.

[3]  R. Olszanecki,et al.  The Anti-Atherosclerotic Action of FFAR4 Agonist TUG-891 in ApoE–Knockout Mice Is Associated with Increased Macrophage Polarization towards M2 Phenotype , 2021, International journal of molecular sciences.

[4]  S. Massberg,et al.  Interplay between inflammation and thrombosis in cardiovascular pathology , 2021, Nature Reviews Cardiology.

[5]  R. Olszanecki,et al.  Anti-Atherosclerotic Potential of Free Fatty Acid Receptor 4 (FFAR4) , 2021, Biomedicines.

[6]  F. Scaglione,et al.  Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation , 2020, Nutrients.

[7]  R. Olszanecki,et al.  Decrease of the pro-inflammatory M1-like response by inhibition of dipeptidyl peptidases 8/9 in THP-1 macrophages - quantitative proteomics of the proteome and secretome. , 2020, Molecular immunology.

[8]  T. Goeser,et al.  NAFLD and cardiovascular diseases: a clinical review , 2020, Clinical Research in Cardiology.

[9]  C. Valério,et al.  NAFLD as a continuum: from obesity to metabolic syndrome and diabetes , 2020, Diabetology & Metabolic Syndrome.

[10]  Shelly C. Lu,et al.  PINE: An Automation Tool to Extract & Visualize Protein-Centric Functional Networks. , 2020, Journal of the American Society for Mass Spectrometry.

[11]  J. Fichna,et al.  Free Fatty Acid Receptors as new potential therapeutic target in Inflammatory Bowel Diseases. , 2019, Pharmacological research.

[12]  P. Scherer,et al.  SREBP-regulated adipocyte lipogenesis is dependent on substrate availability and redox modulation of mTORC1. , 2019, JCI insight.

[13]  R. Olszanecki,et al.  Anti-atherosclerotic action of GW9508 — Free fatty acid receptors activator — In apoE-knockout mice , 2019, Pharmacological reports : PR.

[14]  Y. Liu,et al.  Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues , 2019, Front. Pharmacol..

[15]  J. Lykkesfeldt,et al.  Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease , 2018, Cellular and Molecular Life Sciences.

[16]  R. Olszanecki,et al.  Quantitative proteomics reveals decreased expression of major urinary proteins in the liver of apoE/eNOS‐DKO mice , 2018, Clinical and experimental pharmacology & physiology.

[17]  A. R. Miller,et al.  The GPR120 agonist TUG‐891 promotes metabolic health by stimulating mitochondrial respiration in brown fat , 2018, EMBO molecular medicine.

[18]  N. Vrang,et al.  Mouse models of nonalcoholic steatohepatitis in preclinical drug development. , 2017, Drug discovery today.

[19]  G. Shulman,et al.  Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance. , 2017, Trends in pharmacological sciences.

[20]  A. Soliman.  Potential impact of Paracentrotus lividus extract on diabetic rat models induced by high fat diet/streptozotocin , 2016 .

[21]  P. Boor,et al.  Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis , 2015, Scientific Reports.

[22]  J. Wiśniewski,et al.  Fast and sensitive total protein and Peptide assays for proteomic analysis. , 2015, Analytical chemistry.

[23]  R. Kleemann,et al.  Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology , 2014, PloS one.

[24]  Ling Lin,et al.  Apolipoprotein E-knockout mice on high-fat diet show autoimmune injury on kidney and aorta. , 2014, Biochemical and biophysical research communications.

[25]  Andrew R. Jones,et al.  ProteomeXchange provides globally co-ordinated proteomics data submission and dissemination , 2014, Nature Biotechnology.

[26]  Guido Gerken,et al.  The interaction of hepatic lipid and glucose metabolism in liver diseases. , 2012, Journal of hepatology.

[27]  P. Elliott,et al.  Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human , 2012, Nature.

[28]  S. Watkins,et al.  GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects , 2010, Cell.

[29]  M. Mann,et al.  Universal sample preparation method for proteome analysis , 2009, Nature Methods.

[30]  Pornpimol Charoentong,et al.  ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks , 2009, Bioinform..

[31]  G. Boden.  Obesity and free fatty acids. , 2008, Endocrinology and metabolism clinics of North America.

[32]  D. Tabb,et al.  Proteomic parsimony through bipartite graph analysis improves accuracy and transparency. , 2007, Journal of proteome research.

[33]  I. Dogan,et al.  Apolipoprotein E Gene Polymorphism in Nonalcoholic Fatty Liver Disease , 2007, Digestive Diseases and Sciences.

[34]  Ziwei Gu,et al.  Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[35]  P. Shannon,et al.  Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks , 2003 .

[36]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[37]  Jay D. Horton,et al.  Increased Levels of Nuclear SREBP-1c Associated with Fatty Livers in Two Mouse Models of Diabetes Mellitus* , 1999, The Journal of Biological Chemistry.

[38]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[39]  Congying Wang,et al.  Pyruvate dehydrogenase kinase 4 mediates lipogenesis and contributes to the pathogenesis of nonalcoholic steatohepatitis. , 2018, Biochemical and biophysical research communications.